Pfizer and Seagen have entered a final merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops and commercialises innovative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of $43 billion.
The Boards of Dire
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
